Skip to search boxSkip to navigationSkip to main content

Association between skin and aortic vascular inflammation in patients with psoriasis: A case-cohort study using positron emission tomography/computed tomography

  • Amit K. Dey
    ,
  • Aditya A. Joshi
    ,
  • Abhishek Chaturvedi
    ,
  • Joseph B. Lerman
    ,
  • Tsion M. Aberra
    ,
  • Justin A. Rodante
*Corresponding author for this work
  • National Institutes of Health
    ,
  • University of Arizona
    ,
  • Chevy Chase Dermatology Associates
    ,
  • George Washington University
    ,
  • DermAssociates
    ,
  • National Institutes of Health, Bethesda
Scholary Output:
Contribution to journal
Article
Research
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

<p>IMPORTANCE: Inflammation is critical in the development of atherosclerosis. Psoriasis is a chronic inflammatory skin disease that is associated with increased vascular inflammation by <sup>18</sup>fluorodeoxyglucose positron emission tomography/computed tomography in vivo and future cardiovascular events. It provides a human model to understand the effect of treating inflammation in a target organ (eg, the skin) on vascular diseases. OBJECTIVE: To investigate the association between change in skin disease severity and change in vascular inflammation at 1 year and to characterize the impact of 1 year of anti–tumor necrosis factor therapy on vascular inflammation. DESIGN, SETTING, AND PARTICIPANTS: In this prospective cohort study, 220 participants from outpatient practices were recruited at the US National Institutes of Health. A total of 115 consecutively recruited patients with psoriasis were followed up at 1 year. The study was conducted from January 1, 2013, through October 31, 2016, with data analyzed in November 2016. EXPOSURE: Skin inflammation measured as Psoriasis Area and Severity Index (PASI) score. MAIN OUTCOMES AND MEASURES: Vascular inflammation assessed as target-to-background ratio by <sup>18</sup>fluorodeoxyglucose positron emission tomography/computed tomography. RESULTS: Among the 115 patients, the mean (SD) age at 1-year follow-up was 50.8 (12.8) years and 68 were men (59%). The cohort had a low cardiovascular risk by Framingham risk score and mild-to-moderate psoriasis, with a median PASI score of 5.2 (interquartile range, 3.0-8.9). At follow-up, the total cohort had a median improvement in PASI score of 33%, with use of topical therapy (60%), biological therapy (66%, mostly anti–tumor necrosis factor) and phototherapy (15%) (P < .001). Moreover, improvement in PASI score was associated with improvement in target-to-background ratio of 6%, mainly driven by those with higher responses in PASI score (P < .001). This association persisted beyond traditional risk factors (β = 0.19; 95% CI, 0.012-0.375; P = .03) and was the strongest in those initiated with anti–tumor necrosis factor therapy (β = 0.79; 95% CI, 0.269-1.311; P = .03). CONCLUSIONS AND RELEVANCE: Improvement in psoriasis skin disease severity was associated with improvement in aortic vascular inflammation by <sup>18</sup>fluorodeoxyglucose positron emission tomography/computed tomography, with greater improvement in aortic vascular inflammation observed in those who had higher than 75% reduction in skin disease severity. These findings suggest that controlling remote target organ inflammation (eg, in the skin) may improve vascular diseases; however, randomized clinical trials are needed to confirm these findings.</p>

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 1013-1018 (6 pages)

Journal (Volume, Issue Number)

JAMA Cardiology (Volume 2, Issue 9)

Publication milestones

  • Published - 09/2017

Publication status

Published - 09/2017

ISSN

2380-6583

Publication IDs

  • Scopus: 85030528453
  • PubMed: 28564678

Publication metrics

Metrics

Fractional count
1
Fractional count
0.04
Fractional count
25
Fractional count
0.96
Fractional count
1
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Mentions
1
Captures
106
Citation count
109

Funding Details

Funding/Support: This study was supported by grant HL006193-01 from the National Institutes of Health Intramural Research Program. Dr Gelfand was supported by grant K24-AR-064310 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases.
FundersFunding numbers
NHLBI
ZIAHL006193
NIAMS
-
NHRI
K24-AR-064310